Login / Signup

Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases.

Vinod Kumar RajanaSudha Madhavi PenumakaCevella SarithaRavichandiran VelayuthamDebabrata Mandal
Published in: Anti-inflammatory & anti-allergy agents in medicinal chemistry (2023)
Keyphrases
  • rheumatoid arthritis
  • oxidative stress
  • juvenile idiopathic arthritis
  • drug administration
  • ulcerative colitis
  • hidradenitis suppurativa
  • systemic lupus erythematosus
  • disease activity
  • chemotherapy induced